Immunotherapy and chemo after stomach cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from coming back. You may qualify if you had D2 surgery and your tumor tested positive for PD-L1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with stage III stomach or gastroesophageal junction adenocarcinoma.
- Your tumor has a PD-L1 CPS score of 1 or higher (a lab test shows your cancer has a certain protein).
- You had a type of surgery called D2 gastrectomy, which removes the tumor and nearby lymph nodes.
- Your daily activity level is good (ECOG score 0 or 1, meaning you can do most things yourself).
- You are willing to provide a tumor tissue sample and blood samples for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests giving immunotherapy together with chemotherapy before surgery for certain “locally advanced” cancers at the esophagus-stomach junction. It may help shrink the tumor and improve outcomes by treating the cancer earlier with both immune and chemotherapy approaches.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial tests whether adding an immunotherapy drug (QL1706) to a standard chemotherapy regimen, given before surgery, can help shrink stomach or gastroesophageal junction cancer. The goal is to improve the chance of successful surgery and long-term outcomes.
This trial tests a combination of experimental drugs (IBI343, Sintilimab, and chemotherapy) before and after surgery for a specific type of stomach cancer that is CLDN18.2 positive. The goal is to see if this treatment shrinks the tumor and helps prevent the cancer from coming back.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.